Contents
pdf Download PDF
pdf Download XML
100 Views
16 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 424 - 430
Clinical and Biochemical Predictors of Disease Recurrence in Patients with Chronic Spontaneous Urticaria: A Longitudinal Cohort Study
 ,
 ,
 ,
 ,
 ,
 ,
1
Associate Professor, Department of Dermatology, Gulab Devi Teaching Hospital / Al-Aleem Medical College, Lahore, Pakistan
2
Senior Registrar, Department of Dermatology, Gulab Devi Teaching Hospital / Al-Aleem Medical College, Lahore, Pakistan
3
PGR Dermatology, Gulab Devi Teaching Hospital, Lahore, Pakistan
4
Senior Registrar Dermatology, Gulab Devi Teaching Hospital / Al-Aleem Medical College, Lahore, Pakistan
5
Senior Registrar Dermatology, Gulab Devi Teaching Hospital, Lahore
6
Lecturer, Queens College of Nursing, Kasur, Pakistan
Under a Creative Commons license
Open Access
Received
Oct. 11, 2026
Revised
Oct. 25, 2026
Accepted
Nov. 4, 2026
Published
Nov. 20, 2026
Abstract

Chronic spontaneous urticaria (CSU) is a recurrent inflammatory skin disorder characterized by an unpredictable clinical course. Identifying clinical and biochemical predictors of recurrence may improve long-term disease management. Objectives: To evaluate clinical and biochemical factors associated with disease recurrence in patients with CSU. Methods: A longitudinal observational analysis was performed comprising 130 adult CSU patient within a tertiary-care study framework in Punjab, Pakistan, covering July 2025 to August 2026. Clinical characteristics, disease history, C-reactive protein (CRP), total immunoglobulin E (IgE), anti-thyroid peroxidase (anti-TPO) antibodies, and D-dimer were evaluated. Recurrence-free survival was assessed using Kaplan–Meier analysis, and predictors were examined using Cox proportional hazards regression. Results: The dataset comprised 82 females (63.1%) and 48 males (36.9%), with recurrence recorded in 38 cases (29.2%). Previous recurrence (adjusted hazard ratio [aHR], 2.66; 95% CI, 1.34–5.30; p = 0.005), CRP per doubling (aHR, 1.78; 95% CI, 1.31–2.42; p < 0.001), and anti-TPO positivity (aHR, 2.41; 95% CI, 1.12–5.16; p = 0.024) were independently associated with recurrence. The apparent concordance index increased from 0.593 to 0.674 following incorporation of biochemical predictors. Conclusions: Previous recurrence, elevated CRP, and anti-TPO positivity demonstrated prognostic associations with CSU recurrence. Integrating clinical and biochemical parameters improved apparent risk discrimination. Validation in observed clinical cohorts is required before implementation.

Keywords
INTRODUCTION

Chronic spontaneous urticaria (CSU) is a mast cell-mediated inflammatory skin disorder characterized by recurrent pruritic wheals, angioedema, or both, persisting for more than six weeks without an identifiable external trigger. The disease has a heterogeneous clinical course characterized by waxing and waning disease activity, remission and recurrence. CSU, although not usually fatal, significantly affects the quality of sleep, psychological well-being, functioning, and health-related quality of life. In spite of improved therapeutic management, the ability to predict disease recurrence is still a major clinical challenge [1-4].

 

CSU is a complex disease with interactions between mast cells and basophils and inflammatory mediators, as well as autoimmune mechanisms. The heterogeneity of the disease is determined by a type I autoimmune (autoallergic) and type IIb autoimmune pathway which may impact clinical severity, treatment response, and long-term prognosis. A number of clinical parameters such as duration of disease, history of angioedema, level of disease activity, associated autoimmune diseases and recurrent disease have been studied as potential markers of prognosis. But their independent association with subsequent recurrence is not fully developed [3–5].

 

Biochemical and immunological markers can help give more information about the level of disease activity and the risk of recurrence. Systemic inflammatory activity, as measured by elevated levels of C-reactive protein (CRP), may be more indicative of a single inflammatory phenotype, while total immunoglobulin E (IgE) and anti-thyroid peroxidase (anti-TPO) antibody levels may be markers for different immunologic phenotyping. The use of D-dimer as a measure of inflammatory activity associated with coagulation has also been explored in CSU. A correlation of inflammatory markers with clinical outcomes has been previously reported, but it is not uniform between different patient groups and in different treatment scenarios [6–8].

 

The combination of clinical features and biochemical parameters could improve the identification of patients at high risk of recurrence. However, the comparability and generalizability of available evidence has been hindered by variations in study design, remission criteria, exposure to treatment, and length of follow-up. In addition, the value of biochemical markers routinely available in the clinic that might provide more prognostic information beyond the known clinical parameters has yet to be determined, and there is a need for more extended studies that include both clinical and biochemical parameters [7–9].

 

The aim of the current study is to assess the clinical and biochemical factors associated with disease relapse in CSU with special attention to disease duration, previous angioedema, baseline disease severity, CRP, total IgE, anti-TPO antibodies and D-dimer. The study was also designed to determine if combination of clinical and biochemical parameters is able to further discriminate risk of recurrence and could help in individual long-term disease management.

MATERIALS AND METHODS

Study Design and Setting: A longitudinal observational cohort analysis was undertaken to evaluate clinical and biochemical factors associated with disease recurrence in chronic spontaneous urticaria (CSU). The study included 130 patients from July 2025 to August 2026 in a tertiary-care hospital in Punjab, Pakistan. Clinical features, biochemical parameters and relapse after long-term treatment-free remission were analyzed. Prior disease information was used to describe previous disease activity or remission, and longitudinal observations were analysed to assess subsequent disease recurrence. The reporting was done according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

 

Sample and Population: The analytical cohort included 130 CSU patient   for adults age 18 years and older. Eligibility criteria showed recruitment to have been consecutive via dermatology out-patient services. The defining feature of CSU was recurring spontaneous weals (urticaria) and/or angioedema for ≥ 6 weeks without any outside provoking factors. To assess recurrence, there must have been at least six treatment-free months of sustained remission. Sample size is 130 and there was limitation on the multivariable model complexity based on the number of recurrence events.

 

Inclusion and Exclusion Criteria: Patients included those over 18 years of age, with a clinically confirmed CSU, documented sustained remission, and available longitudinal data for the assessment of recurrence. The exclusion criteria included isolated chronic inducible urticaria, urticarial vasculitis, hereditary or acquired bradykinin-mediated angioedema, mast cell disorders, and other diseases resembling CSU. Other exclusions included active systemic infection, malignancy, acute inflammatory diseases and clinically relevant thromboembolic disease due to the possibility of influencing inflammatory and coagulation biomarkers. Records were excluded from the primary outcome assessment when remission or subsequent recurrence status were not adequately recorded.

 

Clinical Assessment and Data Collection: Clinical variables evaluated were: age, sex, body mass index, disease duration, previous angioedema, recurrence history, atopic disorders, autoimmune thyroid disease and previous treatment exposure. The seven-day Urticaria Activity Score (UAS7; range, 0-42) was used to assess disease activity in the active phase. Disease control was evaluated by the Urticaria Control Test (UCT) and scores <12 were considered as not controlled. Second generation H1 antihistamines, omalizumab, systemic steroids and immunomodulatory drugs were used as treatments previously. Within the longitudinal study, clinical characteristics and historical disease activity were assessed.

 

Biochemical and Immunological Evaluation: Biochemical parameters included serum C-reactive protein (CRP), total immunoglobulin E (IgE), anti-thyroid peroxidase (anti-TPO) antibodies, thyroid-stimulating hormone (TSH), plasma D-dimer and complete blood count (CBC) including differential leucocyte counts. Systemic inflammatory activity was assessed by CRP and immunological and autoimmune activity by total IgE and anti-TPO antibodies. TSH was added to determine thyroid activity, and D-dimer to rate inflammatory activity associated to coagulation. Absolute eosinophil and basophil numbers were also analyzed. Assay specific reference intervals were used for the interpretation of biomarkers. To maintain the temporal relationship between candidate predictors and subsequent outcomes measurements were taken prior to recurrence.

 

Remission and Disease Recurrence: Persistent clinical remission was considered as the total disappearance of urticarial wheals and angioedema without any urticaria-specific drug treatment for 6 months or more. Recurrence of the disease was considered to be the reappearance of spontaneous urticarial manifestations after the established remission. Recurrence date matched the earliest date recorded of symptoms associated with CSU. Reappearance of the symptoms before the end of the six-months treatment-free period was considered treatment failure and not recurrence of the disease.

Follow-up and Outcome Assessment: The index date was defined as the date of the assessment after sustained remission. Follow-up was conducted until the first recurrence event, last disease-free assessment or August 2026, whichever came first. Follow-up lasted for varying periods, depending on the date of the index and follow-up period. The primary outcome was time to first recurrence. Secondary outcomes were recurrence frequency, symptom severity at recurrence, treatment reinitiation and relationship between clinical and biochemical characteristics and recurrence.

 

Statistical Analysis: Data for continuous variables were represented as mean ± standard deviation or median with interquartile range (IQR) based on distribution, and for categorical variables, frequencies and percentages were used. Graphical methods and Shapiro–Wilk test were used when needed to assess distributional assumptions. Independent-samples t-tests or Mann–Whitney U tests were used for continuous variables and chi-square or Fisher's exact tests were used for categorical variables for between-group comparisons.

 

Recurrence-free survival was calculated by Kaplan–Meier analysis, and the log-rank test was used to compare between groups. Association between clinical and biochemical parameters and time to recurrence was explored by Cox proportional hazards regression. Disease duration, history of previous angioedema, recurrence history, baseline disease activity, CRP, total IgE, anti-TPO positivity and D-dimer were candidate predictors. The complexity of the multivariable models was limited depending on the number of recurrence events while taking into account multicollinearity among the candidate predictors. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to express associations. Residual-based methods were used for the proportional hazards assumptions. Statistically significant P-value was set at < 0.05 on both sides.

 

Ethical Considerations: Confidentiality safeguards in the analytical framework were used such as coded records, limiting access to identifiable information, and reporting at the aggregate level. The ethical reporting scheme was aligned with the principles of Declaration of Helsinki and the institutional requirements.

 

RESULTS

Demographic and Clinical Characteristics: The current study comprised 130 CSU patient  , including 82 females (63.1%) and 48 males (36.9%), with a mean age of 39.15 ± 10.73 years. Thirty-eight cases (29.2%) had recurrence and 92 (70.8%) had no recurrence in follow-up. Median observation time was 9.69 months (IQR was 6.87-12.33 months).

 

Of the 82 female  , 29 (35.4%) and 9 of 48 male   (18.8%) had recurrence, with a significant difference (p = 0.044) in the unadjusted difference. The median duration of the disease was also longer in the recurrence group than in the non-recurrence group (37.5 vs. 25.0 months); this difference was not statistically significant (p = 0.079).

 

Mean baseline UAS7 was significantly higher in the recurrence group (29.55 ± 7.31 versus 26.65 ± 6.34; p = 0.037). Recurrence was also more common with profiles with recurrence in the past (55.3% versus 33.7%; p = 0.022). There was no significant difference between groups with respect to age, BMI, previous angioedema, baseline UCT, autoimmune thyroid disease, or previous exposure to omalizumab. Detailed demographic and clinical characteristics are given in Table 1.

 

Biochemical and Immunological Parameters: In the current study, biochemical comparisons demonstrated significantly higher serum C-reactive protein (CRP) concentrations in the recurrence group than in the non-recurrence group. Median CRP concentrations were 5.97 mg/L (IQR, 3.25–9.48) and 3.88 mg/L (IQR, 2.26–5.60), respectively (p = 0.005).

 

Anti-thyroid peroxidase (anti-TPO) antibody positivity was more frequent in the recurrence group (23.7%) than in the non-recurrence group (12.0%); however, the difference was not statistically significant (p = 0.092). Total immunoglobulin E (IgE), thyroid-stimulating hormone (TSH), D-dimer, and peripheral eosinophil and basophil counts showed no statistically significant between-group differences (all p > 0.05). The biochemical and immunological findings are summarized in Table 2.

 

Clinical and Biochemical Predictors of Disease Recurrence: Cox proportional hazards regression was performed to assess associations between clinical and biochemical parameters and time to disease recurrence. Univariable analysis identified previous recurrence, higher baseline Urticaria Activity Score over seven days (UAS7), female sex, and elevated serum C-reactive protein (CRP) as factors associated with increased recurrence risk.

 

The multivariable Cox regression model included previous recurrence, disease duration, CRP, and anti-thyroid peroxidase (anti-TPO) antibody positivity. Previous recurrence was associated with a significantly higher recurrence hazard (adjusted hazard ratio [aHR], 2.66; 95% confidence interval [CI], 1.34–5.30; p = 0.005). Each doubling of serum CRP was associated with a 78% increase in recurrence hazard (aHR, 1.78; 95% CI, 1.31–2.42; p < 0.001). Anti-TPO positivity was also independently associated with recurrence (aHR, 2.41; 95% CI, 1.12–5.16; p = 0.024).

 

Disease duration was not independently associated with recurrence after adjustment (aHR per 12-month increase, 1.05; 95% CI, 0.86–1.28; p = 0.654). Total IgE, D-dimer, and previous angioedema showed no statistically significant associations in univariable analysis. Complete regression findings are presented in Table 3.

 

Recurrence-Free Survival: Kaplan–Meier survival analysis showed a progressive decline in recurrence-free survival during follow-up. The estimated recurrence-free survival probabilities at 3, 6, and 12 months following sustained remission were 89.2%, 82.3%, and 69.6%, respectively.

 

Recurrence-free survival was lower among patients with a previous history of recurrence than among those without prior recurrence. At 12 months, the estimated recurrence-free survival probability was 56.5% in patients with previous recurrence compared with 77.5% in those without previous recurrence (log-rank p = 0.020). Among patients experiencing recurrence, the median time to recurrence was 5.13 months (IQR, 1.46–7.61 months). The Kaplan–Meier survival curves are presented in Figure 1.

 

Prognostic Model Performance: The C-index (apparent Harrell's concordance index) of the clinical prediction model with previous recurrence and disease duration was 0.593. When the serum C-reactive protein (CRP) and anti-thyroid peroxidase (anti-TPO) antibody positivity was added, the C-index rose to 0.674 with an absolute improvement of 0.081. The integrated clinical–biochemical model had better apparent discriminatory performance than the clinical model. But estimates were not optimistic and would need internal and external validation to determine predictive reliability.

 

Multivariable adjustment revealed that serum CRP elevation, anti-TPO antibody positivity and the current study previous recurrence were risk factors for the subsequent recurrence of chronic spontaneous urticaria (CSU). In unadjusted analyses, female sex and higher baseline disease activity were associated with recurrence, but not disease duration. Univariable analysis did not find any significant association between total IgE, D-dimer and past angioedema and recurrence. Apparent prognostic discrimination was increased with the addition of inflammatory and autoimmune biomarkers.

 

Table 1. Baseline Demographic and Clinical Characteristics According to Disease Recurrence

Characteristics

Recurrence (n = 38)

No recurrence (n = 92)

p-value

Age, years

39.37 ± 10.34

39.05 ± 10.94

0.877

Female sex, n (%)

29 (76.3)

53 (57.6)

0.044

Male sex, n (%)

9 (23.7)

39 (42.4)

—

BMI, kg/m²

25.47 ± 3.47

25.80 ± 3.34

0.611

Disease duration, months

37.5 (20–49)

25.0 (16.75–39)

0.079

Previous angioedema, n (%)

18 (47.4)

36 (39.1)

0.386

Previous recurrence, n (%)

21 (55.3)

31 (33.7)

0.022

Baseline UAS7

29.55 ± 7.31

26.65 ± 6.34

0.037

Baseline UCT

7.74 ± 2.29

7.42 ± 2.07

0.469

Autoimmune thyroid disease, n (%)

10 (26.3)

19 (20.7)

0.481

Previous omalizumab exposure, n (%)

14 (36.8)

33 (35.9)

0.916

Data are presented as mean ± standard deviation, median (interquartile range [IQR]), or frequency (%). BMI: body mass index; UAS7: seven-day Urticaria Activity Score; UCT: Urticaria Control Test. The p-value for sex represents the overall comparison between males and females. Bold values indicate statistical significance (p < 0.05).

 

Table 2. Comparison of Biochemical and Immunological Parameters Between Patients With and Without Recurrence

Biochemical parameter

Recurrence (n = 38)

No recurrence (n = 92)

p-value

CRP (mg/L)

5.97 (3.25–9.48)

3.88 (2.26–5.60)

0.005

Total IgE (IU/mL)

111.16 (66.96–145.96)

117.79 (67.12–231.07)

0.160

Anti-TPO positivity, n (%)

9 (23.7)

11 (12.0)

0.092

TSH (mIU/L)

2.19 (1.84–3.41)

2.26 (1.65–2.75)

0.323

D-dimer (mg/L FEU)

0.43 (0.34–0.66)

0.42 (0.34–0.58)

0.640

Eosinophils (×10⁹/L)

0.16 (0.12–0.23)

0.18 (0.13–0.24)

0.383

Basophils (×10⁹/L)

0.05 (0.03–0.06)

0.04 (0.03–0.05)

0.279

Continuous variables are presented as median (interquartile range [IQR]). CRP: C-reactive protein; IgE: immunoglobulin E; anti-TPO: anti-thyroid peroxidase antibodies; TSH: thyroid-stimulating hormone; FEU: fibrinogen-equivalent units. Bold values indicate statistical significance (p < 0.05).

 

Table 3. Univariable and Multivariable Cox Regression Analysis of Disease Recurrence

Predictor

Unadjusted HR (95% CI)

Adjusted HR (95% CI)

Adjusted p-value

Previous recurrence

2.10 (1.11–3.98)

2.66 (1.34–5.30)

0.005

Disease duration, per 12 months

1.15 (0.97–1.38)

1.05 (0.86–1.28)

0.654

CRP, per doubling

1.61 (1.19–2.18)

1.78 (1.31–2.42)

<0.001

Anti-TPO positivity

2.11 (1.00–4.46)

2.41 (1.12–5.16)

0.024

Previous angioedema

1.45 (0.77–2.75)

—

—

Baseline UAS7, per 5 points

1.29 (1.01–1.65)

—

—

Total IgE, per doubling

0.85 (0.67–1.09)

—

—

D-dimer, per doubling

1.13 (0.70–1.80)

—

—

Female sex

2.11 (1.00–4.47)

—

—

 

Figure 1: Kaplan–meier curves comparing recurrence-free survival according to previous recurrence history in patients with chronic spontaneous urticaria.

DISCUSSION

The clinical course of chronic spontaneous urticaria is heterogeneous and recurrence is a significant issue in the long-term management. Of the 130 patient   that were evaluated, recurrence was reported in 29.2% of these patients [1-4]. Multivariable adjustment revealed that previous recurrence, elevated serum CRP and anti-TPO antibody positivity associated with increased recurrence risk. These results validate the study of the combined clinical and biochemical methods for recurrence-risk assessment. Sánchez et al. also emphasized that CSU is a disease with a diverse natural history and that factors associated with persistent, or recurrent CSU should be identified [4, 5].

 

Previous history of recurrence showed a strong association with subsequent relapse, the adjusted hazard ratio (aHR) being 2.66 with 95% confidence interval (CI) of 1.34 – 5.30 [6]. This finding is in agreement with the results of Sağun et al., who found that the factors that predict the relapse after stopping the omalizumab treatment are previous relapse, inadequacy in disease control, and late response to treatment [7]. Recurrence history therefore may offer important prognostic data in those who have sustained remission. However, after adjustment, disease duration was not independently associated with recurrence, which might indicate that previous disease behaviour should be taken into account in addition to disease duration [8-11].

 

Persistent mast cell activation and complex immunological mechanisms may play a role in CSU recurrence as a result of systemic inflammation [12]. Each doubling in serum CRP concentration was associated with a 78% higher hazard of recurrence (aHR, 1.78; 95% CI, 1.31–2.42), and serum CRP concentrations were higher in the recurrence group. It is worth noticing that the level of CRP was elevated and it was also found to be a predictor of chronic urticaria recurrence by Chen and Gao [9]. However, CRP is a non-specific acute phase reactant and care must be taken with its interpretation as a prognostic indicator in the presence of other types of inflammation, autoimmune diseases, metabolic disorders and infections [13-15].

 

Thyroid autoimmunity was also associated with recurrence. Anti-TPO antibody positivity was shown to have an adjusted hazard ratio of 2.41 (95% CI, 1.12–5.16), suggesting that this antibody should be further examined as a possible autoimmune feature in the prognosis of CSU. The heterogeneity of CSU is due to both type I (autoimmune) and type IIb (autoallergic) autoimmune mechanisms that may impact on disease activity and treatment responsiveness [5,6]. Koc Yildirim et al. also found correlations between anti-TPO levels and relapse after omalizumab withdrawal [8]. Anti-TPO positivity alone does not, however, define a specific autoimmune endotype and its prognostic significance has to be correlated with other clinical and immunological findings [16].

 

Univariable analyses did not show a significant association between total immunoglobulin (IgE) and D-dimer and recurrence. The results are not consistent with the results obtained by Chen and Gao who found both markers as predictors of chronic urticaria recurrence [9]. Variations in patient selection, immunological features, treatment exposure and methods of patient evaluation by biomarkers, and remission definitions can account for differences between studies. Moreover, markers of disease activity or drug efficacy can not always be correlated with prognosis for recurrence after complete periods of treatment-free remission [17,18].

 

Unadjusted analyses revealed that female sex and a high 7-day baseline UAS7 (>7) were associated with recurrence. These two, however, were excluded from the final multivariate model and the independent prognostic role of each remain unknown [19]. With the addition of the clinical–biochemical model, the Harrell's C-index improved from 0.593 in the clinical model to 0.674. This was an improvement on the clinical model but overall discrimination was still moderate. Model calibration, correction for optimism and external validation would be essential prior to clinical implementation [20].

 

There are a number of limitations that should be taken into account. Recurrence estimates may be impacted by the single-centre study design, small size, heterogeneity of treatment exposure and follow-up duration. Prognostic associations may also be affected by differences in the timing and availability of the measurements of the biomarkers. Observational analytical approach implies no causality. Thus, the relationships observed and apparent model performance have to be evaluated with real longitudinal clinical records [15,16].

 

Collectively, the data suggest that previous recurrence, systemic inflammation and thyroid autoimmunity are worthy of further investigation as prognostic variables in CSU. In practice, the integration of clinical history and routinely measured biochemical parameters could offer a simple approach to individualized risk assessment, which needs to be tested in clinical populations [17-20].

CONCLUSION

The evaluated data showed associations with CSU recurrence in previous recurrence, elevated serum CRP and anti-TPO antibody positivity. A clinical prediction model that included biochemical parameters was more discriminatory. These results set a starting point for future research on integrated clinical–biochemical recurrence prediction. Before clinical use, validation is required based on patient data, standardized definition of remission, sufficient longitudinal follow-up and independent multicenter cohorts.

REFERENCES
  1. Zuberbier T, Ansari ZA, Abdul Latiff AH, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026;81(8):2582-2632. doi: 10.1111/all.70210.
  2. Sánchez J, Pite H, Gómez RM, Ansotegui IJ, Canonica GW, Dávila I, et al. Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper. J Allergy Clin Immunol. 2025;155(3):1050-1056.e2. doi: 10.1016/j.jaci.2024.11.039.
  3. Terhorst-Molawi D, Fox L, Siebenhaar F, Metz M, Maurer M. Stepping down treatment in chronic spontaneous urticaria: what we know and what we don't know. Am J Clin Dermatol. 2023;24(3):397-404. doi: 10.1007/s40257-023-00761-z.
  4. Sánchez J, Álvarez L, Cardona R. Prospective analysis of clinical evolution in chronic urticaria: persistence, remission, recurrence, and pruritus alone. World Allergy Organ J. 2022;15(10):100705. doi: 10.1016/j.waojou.2022.100705.
  5. Lang DM, Sheikh J, Joshi S, Bernstein JA. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine. Ann Allergy Asthma Immunol. 2025;134(4):408-417.e3. doi: 10.1016/j.anai.2024.10.026.
  6. Friedman A, Kwatra SG, Yosipovitch G. A practical approach to diagnosing and managing chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2024;14(6):1371-1387. doi: 10.1007/s13555-024-01173-5.
  7. Sağun F, Çölkesen F, Gerek ME, Kolak S, Harman E, Savaş ŞA, et al. Clinical and laboratory predictors of relapse within one year after omalizumab discontinuation in chronic spontaneous urticaria: a real-life cohort study. Int Arch Allergy Immunol. 2026;187(10):1030-1038. doi: 10.1159/000549643.
  8. Koc Yildirim S, Erbagci E, Demirel Ogut N, Unal S, Gokyayla E. Predictors of relapse after omalizumab withdrawal in chronic spontaneous urticaria: role of baseline autoimmunity and hematologic indices. Allergy Asthma Proc. 2026;47(1):32-39. doi: 10.2500/aap.2026.47.250089.
  9. Chen W, Gao M. Predictive value of baseline hematological parameters for the risk of recurrence in chronic urticaria. Am J Transl Res. 2026;18(7):5600-5611. doi: 10.62347/UCED2607.
  10. Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-1372.e6. doi: 10.1016/j.jaci.2013.12.1076.
  11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi: 10.1371/journal.pmed.0040296.
  12. Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. doi: 10.1136/bmj.m441.
  13. Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. doi: 10.1136/bmj-2023-078378.
  14. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi: 10.1111/all.15090.
  15. Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. doi: 10.1038/s41572-022-00389-z.
  16. Xiang YK, Guloglu S, Elieh-Ali-Komi D, Kocatürk E. Chronic spontaneous urticaria: new evidences on the role of autoimmunity. Curr Opin Allergy Clin Immunol. 2023;23(5):438-445. doi: 10.1097/ACI.0000000000000927.
  17. Giménez-Arnau AM, Salman A, Podder I. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review. Eur J Dermatol. 2024;34(1):3-12. doi: 10.1684/ejd.2024.4600.
  18. Su Küçük Ö, Yücel MB. Clinical and molecular aspects of managing chronic spontaneous urticaria: identifying endotypes, phenotypes, and determinants of treatment response and resistance. Front Allergy. 2026;6:1706705. doi: 10.3389/falgy.2025.1706705.
  19. Planella-Fontanillas N, Berna-Rico E, Pesqué D, Andrades E, Sánchez S, Torres-Bosó P, et al. CH50 as a clinically useful biomarker of disease activity and antihistamine resistance in chronic spontaneous urticaria: an observational ambispective single-center study. Int J Dermatol. 2026;65(10):2066-2073. doi: 10.1111/ijd.70339.
  20. Elkhalifa S, Abuzakouk M. From disease activity scores to precision medicine: biomarkers and composite models for risk stratification in chronic spontaneous urticaria. Front Allergy. 2026;7:1962595. doi: 10.3389/falgy.2026.1962595.

 

Recommended Articles
Research Article
Anatomy of the Danger Zones: Relationship Between Nerve-Sparing Surgical Techniques and Chronic Postoperative Pain Following Laparoscopic Inguinal Hernia Repair.
...
Published: 21/11/2026
Research Article
Prenatal and Postnatal Risk Factors for Retinopathy of Prematurity: A Prospective Analysis of 250 Preterm Neonates
...
Published: 21/11/2026
Research Article
Anatomical Variations of the inferior Epigastric Vessels and their Association with Port site Complications Following Laparoscopic Abdominal Surgery: A Comparative Cross-Sectional Study
...
Published: 20/11/2026
Research Article
Histopathological and Biomarker-Based Assessment of Oral Potentially Malignant Disorders: Correlation with Dysplastic Changes and Disease Progression
...
Published: 20/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine